Freenome, Inc.: Multiomics Transition Catalyzes $393.9 Million Liquidity Reset at Brisbane Facility as FDA Premarket Approval Triggers Exact Sciences Milestone
Date : 2026-08-28
Reading : 79
HDIN Executive Takeaways
1. Freenome, Inc. [NASDAQ: FRNM] resolved a 6.30-month pre-merger liquidity deficit ($102.02 million standalone cash at June 30, 2026) via $295.5 million in net de-SPAC proceeds and a $100.0 million milestone from Abbott Laboratories [NYSE: ABT].
2. Physical operations anchor on a 120,000-square-foot, 80% automated Brisbane clinical laboratory, backed by sole-source supply contracts with Illumina, Inc. [NASDAQ: ILMN] and New England Biolabs.
3. Institutional control consolidates under four entities holding a 49.3% voting block, while $439.0 million in undiscounted lease and cloud liabilities limit discretionary operational flexibility through 2035.
Figure Strategic Analysis of Freenome: Multiomics Innovation and Commercial Scalability
Financial Analysis, Runway Modeling, and Unit Economics Scalability
Historical financial disclosures from the Form S-1 registration statement confirm that Freenome, Inc.'s cost structure has functioned primarily as an R&D-driven mechanism rather than a standard commercial operational model. Prior to the Class III Premarket Approval (PMA) of SimpleScreen CRC v1 in July 2026, all clinical assay development, trial validation, and pre-launch reagent consumption were fully expensed within Research and Development.
Table REENOME, INC. CORE HISTORICAL FINANCIAL STATEMENT AUDIT
The top-line expansion in FY2025 to $30.41 million was driven by $27.14 million in license revenue from Exact Sciences Corporation [NASDAQ: EXAS] (acquired by Abbott Laboratories [NYSE: ABT] in March 2026) following antitrust clearance on November 7, 2025. Service revenue, derived from UK-based test kit sales via Freenome Limited and multiomics research services for Roche Holding AG [SWX: ROG], generated $2.88 million in FY2024, $3.27 million in FY2025, and $1.34 million in the six months ended June 30, 2026.
R&D expenditures accounted for 76.6% of total operating costs in FY2024 and 77.6% in FY2025. In the first six months of 2026, R&D expanded 12.1% year-over-year to $106.39 million, driven by a 147% surge in materials and laboratory supplies from $9.68 million to $23.87 million as the company commenced its Early Access Program (EAP). Laboratory personnel compensation accounted for $36.62 million, while facility depreciation, equipment amortization, and leasehold allocations totaled $30.68 million in H1-2026. G&A overhead fell from $66.54 million in FY2024 to $54.82 million in FY2025 following a 20% workforce reduction in April 2024, stabilizing at $26.62 million in H1-2026.
Table PRE-TRANSACTION LIQUIDITY AND RUNWAY SCENARIO MODEL
*Base Liquidity: $102.02M Available Pre-Merger June 30, 2026)
Prior to closing its de-SPAC business combination with Perceptive Capital Solutions Corp. [NASDAQ: PCSC] on July 20, 2026, Freenome's standalone liquid assets totaled $102.02 million ($85.47 million cash and cash equivalents, $16.56 million short-term marketable securities, excluding $9.56 million in restricted cash securing letters of credit). Under actual H1-2026 operational cash consumption of $97.11 million ($16.19 million per month), standalone liquidity stood at 6.30 months.
Normalized FY2025 cash burn—adjusting for the one-time $75.0 million upfront license fee received from Exact Sciences Corporation in November 2025—totaled $185.67 million ($15.47 million per month), indicating an underlying run-rate of 6.59 months. This deficit triggered going-concern explanatory disclosures by independent auditors Ernst & Young LLP.
Liquidity was augmented post-period by $295.5 million in net proceeds from the de-SPAC transaction (including a $240.0 million PIPE at $10.00 per share) and a $100.0 million regulatory milestone triggered by the July 2026 FDA approval of SimpleScreen CRC v1, extending combined pro forma liquidity above $393.9 million through 2028.
Gross margin progression toward an estimated 75% to 80% long-term target relies on four structural operating levers:
* Inventory Capitalization Shift: Initial capitalization of $1.60 million in qualifying raw materials occurred in June 2026, shifting assay validation costs from direct R&D expensing into inventory assets.
* Centralized Laboratory Automation: Brisbane's 120,000-square-foot facility operates at 80% automation (advancing to 95% for SimpleScreen CRC v2), distributing fixed leasehold depreciation across expanded test volume.
* Direct Royalty Drop-Through: Royalties scaling up to 10% of net sales from Abbott Laboratories on U.S. CRC testing (activated above a 20% product gross margin) and mid-single-digit to mid-teens percentages on ex-U.S. net sales from Roche Holding AG carry a 100% gross margin contribution.
* Single-Draw Multiomics Assay Architecture: Common assay processing multiplexes colorectal, lung, and personalized cancer detection (PCD) panels from a single blood draw, eliminating duplicate sequencing runs.
Table RIGID CONTRACTUAL AND LEASE COMMITMENT SCHEDULE (Undiscounted Operational Obligations as of June 30, 2026)
Discounted lease liabilities on the balance sheet total $193.00 million in non-current liabilities and $11.19 million in current liabilities, calculated using an 11.3% incremental borrowing rate.
Clinical Validation, IP Moats, and Supply Chain Infrastructure
Table FREENOME MULTIOMICS CLINICAL PIPELINE PERFORMANCE MATRIX
Freenome's technological platform integrates non-bisulfite base-level cell-free DNA (cfDNA) methylation sequencing, ribonucleic acid (RNA) expression, circulating plasma proteins, and tumor-associated autoantibodies (AAbs). Computational deconvolution is executed via proprietary Fragment-Level Deep Learning (FLDL) models, which generate nucleotide sequence embeddings optimized via attention-mechanism weighting.
The SimpleScreen CRC v2 assay captured 3-fold higher cfDNA molecules per sample and deployed mean targeted sequencing depths of 2,000x or greater. This improved Advanced Precancerous Lesion (APL/AA) sensitivity to 18.2% and High-Grade Dysplasia (HGD) sensitivity to 41.9%, modeling a 9.5% reduction in colorectal cancer incidence and mortality relative to v1.
The global Total Addressable Market (TAM) is anchored on 120 million average-risk U.S. adults aged 45 and older (Serviceable Addressable Market, or SAM), of which 40 million to 50 million individuals remain unscreened (Serviceable Obtainable Market, or SOM). Clinical risk overlap models demonstrate that 84% (approximately 100 million individuals) within the primary CRC screening cohort qualify for at least one additional solid tumor screen (lung, breast, liver) based on smoking, body mass index, or metabolic history; 42% qualify for two or more.
Factoring in 17 million non-CRC high-risk individuals and the proposed $509 per-test reimbursement rate under the federal Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, the aggregate addressable multi-cancer screening market reaches $50.0 billion.
Table GLOBAL INTELLECTUAL PROPERTY AND PATENT ARCHITECTURE (194 Total Assets: 60 Issued Patents, 134 Pending Apps)
The intellectual property moat faces direct operational exposure via upstream reagent providers. Biomodal Limited and Children's Medical Center Corporation have filed patent infringement litigation against Freenome's sole-source enzyme provider, New England Biolabs, asserting infringement across eight patents. Freenome's defense relies on the doctrine of patent exhaustion, though three asserted patent claims were previously invalidated under 35 U.S.C. § 101. Freenome holds no material active in-licensing agreements with Stanford University or other academic institutions.
Physical and operational footprints encompass:
* Central Laboratory (Brisbane, Calif.): 335,419 total leased square feet across Buildings I and III at Genesis Marina Campus (3300 Marina Blvd), including a 120,000-square-foot CLIA-certified, CAP-accredited clinical processing laboratory holding an 11-year lease expiring March 31, 2035. During the registrational PREEMPT CRC study across 201 centers, this single facility processed 34,224 clinical tests.
* European Logistics Hub (Nottingham, United Kingdom): Freenome Limited (acquired via Oncimmune Ltd in May 2023 for $16.20 million, comprising $1.60 million equity consideration and $14.50 million debt settlement) produces and distributes EarlyCDT Lung across the UK National Health Service (NHS) and European networks.
* Primary Equipment Dependencies: Illumina, Inc. serves as sole-source vendor for Next-Generation Sequencing (NGS) instruments, flow cells, and reagents under a supply agreement executed January 2024 extending to 2033 (FY2025 spend: $7.80 million), featuring tiered volume discounting without minimum purchase quotas. New England Biolabs provides DNA analysis enzymes under a 10-year contract signed February 2022 (FY2025 spend: $3.60 million), enforcing quarterly binding forecast commitments.
Table STRATEGIC PARTNERSHIP MILESTONE & ROYALTY WATERFALL
Governance Architecture, Capital Restructuring, and HDIN Institutional Verdict
The de-SPAC transaction on July 20, 2026, reconstituted Freenome, Inc.'s capitalization. Aggregate liquidation preferences of $1.351 billion spanning 212,541,832 Series Seed-1 through Series F convertible preferred shares (carrying value of $1.363 billion) were converted into common stock at an exchange ratio of 0.282895, establishing a single-class equity structure with 107,446,814 common shares outstanding as of August 8, 2026.
Table PRO FORMA OWNERSHIP DISTRIBUTION AND PRINCIPAL SHAREHOLDERS (Post-Merger Capitalization Baseline: 107,446,814 Common Shares)
Table EXECUTIVE COMPENSATION AND MILESTONE RETENTION AUDIT (Fiscal Year 2025 Reported Figures)
Governance and executive incentive provisions include:
* Clinical Milestone Contract: CSO Jimmy Lin holds cash retention agreements totaling $950,000 ($300,000 paid upon PMA receipt; $150,000 paid on topline PREEMPT readout; $500,000 contingent on USPSTF Grade A/B designation).
* Anti-Dilution Grants: CEO Aaron Elliott maintains anti-dilution equity rights securing a 0.5% post-merger common share floor in stock options and a 0.5% floor in RSUs (totaling approximately 567,000 units).
* Liquidity Lock-up and RSU Settlements: Mandatory 180-day lock-up agreements expire January 20, 2027. On this date, 2,833,838 service-vested RSUs with Liquidity Event Requirements (LER) convert into freely tradable common stock. Early unlock exemptions apply to sponsor founder shares post-December 17, 2026, if closing share prices equal or exceed $12.00 for 20 out of 30 consecutive trading days.
* Defensive Mechanisms: Corporate bylaws enforce a classified, staggered board (Class I, II, and III directors serving three-year cycles, removable solely for cause via a 66.7% supermajority vote), complete prohibition of shareholder action via written consent, exclusive board authority to call special meetings, and authorization of 10,000,000 blank-check preferred shares.
HDIN Research's institutional verdict identifies an operational trade-off within Freenome's structure. Management has offloaded commercialization execution and SG&A overhead by delegating frontline sales of SimpleScreen CRC v1 to Abbott Laboratories' 1,400-person commercial field force, while capturing non-dilutive milestones ($700.0 million potential) and retaining exclusive ownership of combined multiomics PCD panels.
However, near-term financial leverage remains constrained. Laboratory testing performed for Abbott Laboratories is legally bound to at-cost pricing, precluding standalone central laboratory margin extraction on base colorectal volume.
The $50.0 million convertible note held by Exact Sciences introduces dilution or share-price resistance via its $15.00 mandatory conversion trigger. Furthermore, while the $393.9 million combined capital pool resolves immediate insolvency risks, the company remains burdened by $439.0 million in fixed facility lease and non-cancelable cloud compute liabilities through 2035. Sustained valuation stability hinges entirely on securing USPSTF Grade A/B inclusion to unlock Abbott's $500.0 million commercial milestone and trigger broad Medicare reimbursement prior to the depletion of existing reserves in 2028.
Presentation Download & Video Access
Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research
HDIN Research is a premier global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at http://www.hdinresearch.com.
2026 AI Transparency Footer
This intelligence report was authored by HDIN Research analysts following a rigorous audit of official corporate filings. AI was utilized for massive-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards.
1. Freenome, Inc. [NASDAQ: FRNM] resolved a 6.30-month pre-merger liquidity deficit ($102.02 million standalone cash at June 30, 2026) via $295.5 million in net de-SPAC proceeds and a $100.0 million milestone from Abbott Laboratories [NYSE: ABT].
2. Physical operations anchor on a 120,000-square-foot, 80% automated Brisbane clinical laboratory, backed by sole-source supply contracts with Illumina, Inc. [NASDAQ: ILMN] and New England Biolabs.
3. Institutional control consolidates under four entities holding a 49.3% voting block, while $439.0 million in undiscounted lease and cloud liabilities limit discretionary operational flexibility through 2035.
Figure Strategic Analysis of Freenome: Multiomics Innovation and Commercial Scalability
Financial Analysis, Runway Modeling, and Unit Economics ScalabilityHistorical financial disclosures from the Form S-1 registration statement confirm that Freenome, Inc.'s cost structure has functioned primarily as an R&D-driven mechanism rather than a standard commercial operational model. Prior to the Class III Premarket Approval (PMA) of SimpleScreen CRC v1 in July 2026, all clinical assay development, trial validation, and pre-launch reagent consumption were fully expensed within Research and Development.
Table REENOME, INC. CORE HISTORICAL FINANCIAL STATEMENT AUDIT
| Financial Metric (US$ Thousands) | FY2024 | FY2025 | 6M-2025 | 6M-2026 |
|---|---|---|---|---|
| License & Collaboration Revenue | $0 | $27,139 | $0 | $5,155 |
| Service & Other Revenue | $2,882 | $3,270 | $1,495 | $1,341 |
| Total Revenue | $2,882 | $30,409 | $1,495 | $6,496 |
| Cost of Services (COGS) | $2,564 | $1,944 | $884 | $937 |
| Research & Development (R&D) Expenses | $225,749 | $197,117 | $94,865 | $106,387 |
| General & Administrative (G&A) Expenses | $66,542 | $54,817 | $26,008 | $26,624 |
| Total Operating Expenses | $294,855 | $253,878 | $121,757 | $133,948 |
| Operating Loss | $(291,973) | $(223,469) | $(120,262) | $(127,452) |
| Net Loss | $(274,421) | $(219,343) | $(116,605) | $(132,588) |
| Net Loss Attributable to Common Stockholders | $(281,273) | $(219,343) | $(116,605) | $(132,588) |
| Cash Flow from Operations | $(196,367) | $(110,669) | $(99,646) | $(97,110) |
The top-line expansion in FY2025 to $30.41 million was driven by $27.14 million in license revenue from Exact Sciences Corporation [NASDAQ: EXAS] (acquired by Abbott Laboratories [NYSE: ABT] in March 2026) following antitrust clearance on November 7, 2025. Service revenue, derived from UK-based test kit sales via Freenome Limited and multiomics research services for Roche Holding AG [SWX: ROG], generated $2.88 million in FY2024, $3.27 million in FY2025, and $1.34 million in the six months ended June 30, 2026.
R&D expenditures accounted for 76.6% of total operating costs in FY2024 and 77.6% in FY2025. In the first six months of 2026, R&D expanded 12.1% year-over-year to $106.39 million, driven by a 147% surge in materials and laboratory supplies from $9.68 million to $23.87 million as the company commenced its Early Access Program (EAP). Laboratory personnel compensation accounted for $36.62 million, while facility depreciation, equipment amortization, and leasehold allocations totaled $30.68 million in H1-2026. G&A overhead fell from $66.54 million in FY2024 to $54.82 million in FY2025 following a 20% workforce reduction in April 2024, stabilizing at $26.62 million in H1-2026.
Table PRE-TRANSACTION LIQUIDITY AND RUNWAY SCENARIO MODEL
| Scenario Architecture | Monthly Burn Rate | Calculated Runway | Estimated Cash Depletion Window |
|---|---|---|---|
| Scenario A: Actual H1-2026 Burn Rate | $16.19 Million / Month | 6.30 Months | Early January 2027 |
| Scenario B: Normalized FY2025 Burn Rate | $15.47 Million / Month | 6.59 Months | Mid-January 2027 |
| Scenario C: Unadjusted FY2025 Burn Rate | $9.22 Million / Month | 11.06 Months | May 2027 |
Prior to closing its de-SPAC business combination with Perceptive Capital Solutions Corp. [NASDAQ: PCSC] on July 20, 2026, Freenome's standalone liquid assets totaled $102.02 million ($85.47 million cash and cash equivalents, $16.56 million short-term marketable securities, excluding $9.56 million in restricted cash securing letters of credit). Under actual H1-2026 operational cash consumption of $97.11 million ($16.19 million per month), standalone liquidity stood at 6.30 months.
Normalized FY2025 cash burn—adjusting for the one-time $75.0 million upfront license fee received from Exact Sciences Corporation in November 2025—totaled $185.67 million ($15.47 million per month), indicating an underlying run-rate of 6.59 months. This deficit triggered going-concern explanatory disclosures by independent auditors Ernst & Young LLP.
Liquidity was augmented post-period by $295.5 million in net proceeds from the de-SPAC transaction (including a $240.0 million PIPE at $10.00 per share) and a $100.0 million regulatory milestone triggered by the July 2026 FDA approval of SimpleScreen CRC v1, extending combined pro forma liquidity above $393.9 million through 2028.
Gross margin progression toward an estimated 75% to 80% long-term target relies on four structural operating levers:
* Inventory Capitalization Shift: Initial capitalization of $1.60 million in qualifying raw materials occurred in June 2026, shifting assay validation costs from direct R&D expensing into inventory assets.
* Centralized Laboratory Automation: Brisbane's 120,000-square-foot facility operates at 80% automation (advancing to 95% for SimpleScreen CRC v2), distributing fixed leasehold depreciation across expanded test volume.
* Direct Royalty Drop-Through: Royalties scaling up to 10% of net sales from Abbott Laboratories on U.S. CRC testing (activated above a 20% product gross margin) and mid-single-digit to mid-teens percentages on ex-U.S. net sales from Roche Holding AG carry a 100% gross margin contribution.
* Single-Draw Multiomics Assay Architecture: Common assay processing multiplexes colorectal, lung, and personalized cancer detection (PCD) panels from a single blood draw, eliminating duplicate sequencing runs.
Table RIGID CONTRACTUAL AND LEASE COMMITMENT SCHEDULE (Undiscounted Operational Obligations as of June 30, 2026)
| Commitment Horizon / Year | Facility Lease Commitments (US$M) | Cloud Compute & Purchase Order Commitments (US$M) |
|---|---|---|
| H2 2026 (July 1 – December 31) | $16.03 | $4.16 |
| FY2027 | $32.87 | $8.25 |
| FY2028 | $33.94 | Cloud Commitment Pool (Extending to 2029) |
| FY2029 | $35.05 | $119.10 Total Non-Cancelable AWS Commitments |
| FY2030 | $36.20 | — |
| 2031 – March 31, 2035 | $165.80 | — |
| Total Contractual Commitments | $319.89 Million | $131.51 Million |
Discounted lease liabilities on the balance sheet total $193.00 million in non-current liabilities and $11.19 million in current liabilities, calculated using an 11.3% incremental borrowing rate.
Clinical Validation, IP Moats, and Supply Chain Infrastructure
Table FREENOME MULTIOMICS CLINICAL PIPELINE PERFORMANCE MATRIX
| Product Asset | Regulatory Status | Trial Scale / Validation Cohort | Clinical Sensitivity / Specificity Performance |
|---|---|---|---|
| SimpleScreen™ CRC v1 | FDA Class III PMA Approved (July 2026)U.S. Distribution Partner: Abbott | PREEMPT CRC TrialEnrollment: N = 48,995Laboratory Tests: 34,224Global Sites: 201 | • CRC Sensitivity: 81.1% (Weighted) • Specificity: 90.4% (Average Colorectal Neoplasia, ACN)• Advanced Adenoma (AA): 13.7% • High-Grade Dysplasia: 30.5% • Stage I CRC Sensitivity: 64.0% |
| SimpleScreen™ CRC v2 | Clinical Validation Completed (July 2026)Algorithm Locked | Validation Cohort: • CRC: N = 85 • Advanced Precancerous Lesions (APL/AA): N = 1,500 • High-Grade Dysplasia (HGD): N = 150 |
• CRC Sensitivity: 80.4% • Specificity: 90.0% • Precancerous Lesion Detection (APL/AA): 18.2% • High-Grade Dysplasia: 41.9% • Stage I Sensitivity: 52% (T1: 39.9%; T2: 81.2%) • Stage II: 100%; Stage III: 97.3%; Stage IV: 100% |
| SimpleScreen™ Lung v1 | FDA Breakthrough Device Designation (IVD)LDT Launch Target: 2H 2026(Protein-Only Platform) | • PCD Vallania Study: N = 636 Cohort • PROACT Lung Study: Approximately N = 8,000 Enrollment Target |
• Overall Lung Cancer Sensitivity: 85.7% @ 50% Specificity • Multiomics Sensitivity: 80.4% @ 75% Specificity • Stage I Sensitivity: 76.6% @ 50% Specificity • Stage II Sensitivity: 90.8% @ 50% Specificity |
| Personalized Cancer Detection (PCD) | Discovery PhaseLDT Rollout Target: 2027 | Discovery Cohorts: • Vallania Biobank • Multi-Cancer Detection Panels |
• Common assay platform targeting 10+ solid tumor indications • CSO Classifier Algorithm development across multiple cancer types |
Freenome's technological platform integrates non-bisulfite base-level cell-free DNA (cfDNA) methylation sequencing, ribonucleic acid (RNA) expression, circulating plasma proteins, and tumor-associated autoantibodies (AAbs). Computational deconvolution is executed via proprietary Fragment-Level Deep Learning (FLDL) models, which generate nucleotide sequence embeddings optimized via attention-mechanism weighting.
The SimpleScreen CRC v2 assay captured 3-fold higher cfDNA molecules per sample and deployed mean targeted sequencing depths of 2,000x or greater. This improved Advanced Precancerous Lesion (APL/AA) sensitivity to 18.2% and High-Grade Dysplasia (HGD) sensitivity to 41.9%, modeling a 9.5% reduction in colorectal cancer incidence and mortality relative to v1.
The global Total Addressable Market (TAM) is anchored on 120 million average-risk U.S. adults aged 45 and older (Serviceable Addressable Market, or SAM), of which 40 million to 50 million individuals remain unscreened (Serviceable Obtainable Market, or SOM). Clinical risk overlap models demonstrate that 84% (approximately 100 million individuals) within the primary CRC screening cohort qualify for at least one additional solid tumor screen (lung, breast, liver) based on smoking, body mass index, or metabolic history; 42% qualify for two or more.
Factoring in 17 million non-CRC high-risk individuals and the proposed $509 per-test reimbursement rate under the federal Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, the aggregate addressable multi-cancer screening market reaches $50.0 billion.
Table GLOBAL INTELLECTUAL PROPERTY AND PATENT ARCHITECTURE (194 Total Assets: 60 Issued Patents, 134 Pending Apps)
| Technology Classification | Issued Patents | Pending Patent Assets | Statutory Expiry Timeline |
|---|---|---|---|
| Epigenetics, Proteomics & Autoantibodies (AAbs) | 3 U.S. Issued Patents | 8 U.S. Applications / 1 PCT Application | 2041–2045 |
| Multi-Omics & Transcription Profiles | 0 U.S. Issued Patents | 7 U.S. Applications / 2 Provisional Applications | 2039–2045 |
| Wet Chemistry & 5hmC Sequencing | 3 U.S. Issued Patents | 6 U.S. Applications / 1 PCT Application | 2031–2045 |
| Machine Learning & FLDL Algorithms | 4 U.S. Issued Patents | 2 U.S. Applications / 1 PCT Application | 2039–2046 |
| International Jurisdictions | 45 Non-U.S. Issued Patents | 107 Non-U.S. Patent Applications | Coverage: EPO, China (CN), Japan (JP), South Korea (KR), Australia (AU) |
The intellectual property moat faces direct operational exposure via upstream reagent providers. Biomodal Limited and Children's Medical Center Corporation have filed patent infringement litigation against Freenome's sole-source enzyme provider, New England Biolabs, asserting infringement across eight patents. Freenome's defense relies on the doctrine of patent exhaustion, though three asserted patent claims were previously invalidated under 35 U.S.C. § 101. Freenome holds no material active in-licensing agreements with Stanford University or other academic institutions.
Physical and operational footprints encompass:
* Central Laboratory (Brisbane, Calif.): 335,419 total leased square feet across Buildings I and III at Genesis Marina Campus (3300 Marina Blvd), including a 120,000-square-foot CLIA-certified, CAP-accredited clinical processing laboratory holding an 11-year lease expiring March 31, 2035. During the registrational PREEMPT CRC study across 201 centers, this single facility processed 34,224 clinical tests.
* European Logistics Hub (Nottingham, United Kingdom): Freenome Limited (acquired via Oncimmune Ltd in May 2023 for $16.20 million, comprising $1.60 million equity consideration and $14.50 million debt settlement) produces and distributes EarlyCDT Lung across the UK National Health Service (NHS) and European networks.
* Primary Equipment Dependencies: Illumina, Inc. serves as sole-source vendor for Next-Generation Sequencing (NGS) instruments, flow cells, and reagents under a supply agreement executed January 2024 extending to 2033 (FY2025 spend: $7.80 million), featuring tiered volume discounting without minimum purchase quotas. New England Biolabs provides DNA analysis enzymes under a 10-year contract signed February 2022 (FY2025 spend: $3.60 million), enforcing quarterly binding forecast commitments.
Table STRATEGIC PARTNERSHIP MILESTONE & ROYALTY WATERFALL
| Partner Entity | Upfront Payment / Equity Investment | Capital Injection & R&D Funding | Regulatory / Commercialization Milestones | Commercial Terms |
|---|---|---|---|---|
| Abbott Laboratories(Exact Sciences Corporation) | • $75.0M Upfront Payment (Nov 2025)• $50.0M 5% Convertible Note Due August 2030 | • $20.0M Annual R&D Co-Funding• $60.0M Three-Year Funding Pool• $17.2M Received in Q2 FY2026 | • $100.0M FDA PMA Milestone Achieved (July 2026)• $100.0M Second-Generation Product Milestone• $500.0M USPSTF Grade A/B Recommendation Milestone | • Central Laboratory Testing Model• At-Cost Testing Services• Tiered Royalties Up to 10% of Net Revenue |
| Roche Sequencing Solutions(SWX: ROG) | • $75.0M Option Fee• $75M 5% Convertible Note Converted in July 2026 | • $24.0M SBX Research & Development Milestone Pool | • $100.0M Ex-U.S. Commercial Launch Milestones | • Low Single-Digit to Mid-Teens Royalties Based on Net Sales |
Governance Architecture, Capital Restructuring, and HDIN Institutional Verdict
The de-SPAC transaction on July 20, 2026, reconstituted Freenome, Inc.'s capitalization. Aggregate liquidation preferences of $1.351 billion spanning 212,541,832 Series Seed-1 through Series F convertible preferred shares (carrying value of $1.363 billion) were converted into common stock at an exchange ratio of 0.282895, establishing a single-class equity structure with 107,446,814 common shares outstanding as of August 8, 2026.
Table PRO FORMA OWNERSHIP DISTRIBUTION AND PRINCIPAL SHAREHOLDERS (Post-Merger Capitalization Baseline: 107,446,814 Common Shares)
| Shareholder Entity / Group | Class / Source of Ownership | Total Share Count | Voting Percentage |
|---|---|---|---|
| Roche Holding AG (Roche Holdings) | Series F Preferred Shares & Convertible Note Conversion | 18,692,766 Shares | 17.4% |
| RA Capital Management | Series F Preferred Shares & PIPE Allocation | 15,367,270 Shares | 14.3% |
| Perceptive Advisors (Sponsor Group) | Series F Preferred Shares, PIPE Financing & Convertible Securities | 13,314,347 Shares | 12.4% |
| Andreessen Horowitz (a16z) | Venture Series A–F Investment Holdings | 5,571,599 Shares | 5.2% |
| Top-4 Institutional Consortium | Combined Institutional Ownership | 52,945,982 Shares | 49.3% |
| T. Rowe Price Associates | Growth Institutional Holdings | 4,007,244 Shares | 3.7% |
| Fidelity Management & Research (FMR LLC) | Growth Fund Holdings | 2,562,292 Shares | 2.4% |
| Legacy Freenome Pre-Merger Equity Holders | Preferred / Common Stock Conversion | 68,065,000 Shares | 63.4% |
| PIPE Financing Consortium | $10.00 per Share Cash Investment | 24,000,000 Shares | 22.3% |
| PCSC SPAC Public Shareholders | Class A Common Stock Holdings | 6,478,000 Shares | 6.0% |
| Roche Convertible Note Conversion | $12.00 per Share Conversion Price | 6,460,616 Shares | 6.0% |
| Perceptive SPAC Sponsor Promoters | Founder Capital Class Shares | 2,443,000 Shares | 2.3% |
| Executive Officers & Directors (10 Individuals) | Management Equity Pool | 5,157,447 Shares | 4.8% |
Table EXECUTIVE COMPENSATION AND MILESTONE RETENTION AUDIT (Fiscal Year 2025 Reported Figures)
| Executive / Role | Base Salary (US$) | Annual Bonus (US$) | Stock RSUs (US$) | Option Grants (US$) | Total Compensation (US$) |
|---|---|---|---|---|---|
| Aaron Elliott, Ph.D.Chief Executive Officer | $513,750(Base Salary: $685K) | $513,750(100% Target Bonus) | $5,849,767 | $3,797,865 | $10,688,847 |
| Riley EnnisChief Product Officer / Co-Founder | $546,000 | $327,600(120% Target Bonus) | $1,549,999 | $2,014,890 | $4,438,489 |
| Jimmy Lin, M.D.Chief Scientific Officer(Former Natera Executive) | $530,000 | $212,000(100% Target Bonus) | $1,050,002 | $1,364,927 | $3,156,929 |
| Linh H. LeChief Financial Officer | $301,288(Base Salary: $485K) | $150,644(100% Target Bonus) | $899,997 | $1,174,761 | $2,557,562 |
Governance and executive incentive provisions include:
* Clinical Milestone Contract: CSO Jimmy Lin holds cash retention agreements totaling $950,000 ($300,000 paid upon PMA receipt; $150,000 paid on topline PREEMPT readout; $500,000 contingent on USPSTF Grade A/B designation).
* Anti-Dilution Grants: CEO Aaron Elliott maintains anti-dilution equity rights securing a 0.5% post-merger common share floor in stock options and a 0.5% floor in RSUs (totaling approximately 567,000 units).
* Liquidity Lock-up and RSU Settlements: Mandatory 180-day lock-up agreements expire January 20, 2027. On this date, 2,833,838 service-vested RSUs with Liquidity Event Requirements (LER) convert into freely tradable common stock. Early unlock exemptions apply to sponsor founder shares post-December 17, 2026, if closing share prices equal or exceed $12.00 for 20 out of 30 consecutive trading days.
* Defensive Mechanisms: Corporate bylaws enforce a classified, staggered board (Class I, II, and III directors serving three-year cycles, removable solely for cause via a 66.7% supermajority vote), complete prohibition of shareholder action via written consent, exclusive board authority to call special meetings, and authorization of 10,000,000 blank-check preferred shares.
HDIN Research's institutional verdict identifies an operational trade-off within Freenome's structure. Management has offloaded commercialization execution and SG&A overhead by delegating frontline sales of SimpleScreen CRC v1 to Abbott Laboratories' 1,400-person commercial field force, while capturing non-dilutive milestones ($700.0 million potential) and retaining exclusive ownership of combined multiomics PCD panels.
However, near-term financial leverage remains constrained. Laboratory testing performed for Abbott Laboratories is legally bound to at-cost pricing, precluding standalone central laboratory margin extraction on base colorectal volume.
The $50.0 million convertible note held by Exact Sciences introduces dilution or share-price resistance via its $15.00 mandatory conversion trigger. Furthermore, while the $393.9 million combined capital pool resolves immediate insolvency risks, the company remains burdened by $439.0 million in fixed facility lease and non-cancelable cloud compute liabilities through 2035. Sustained valuation stability hinges entirely on securing USPSTF Grade A/B inclusion to unlock Abbott's $500.0 million commercial milestone and trigger broad Medicare reimbursement prior to the depletion of existing reserves in 2028.
Presentation Download & Video Access
Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research
HDIN Research is a premier global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at http://www.hdinresearch.com.
2026 AI Transparency Footer
This intelligence report was authored by HDIN Research analysts following a rigorous audit of official corporate filings. AI was utilized for massive-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards.